Tradestie Institutional Equity Comparison Engine

LCTX vs ACRS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Options & Structure while ACRS counters with relative strength in Momentum & Technical. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus ACRS at N/M Forward P/E and -1412.4% operating margin (-55.1% YoY). In options structure, LCTX sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against ACRS sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs ACRS N/M Fwd P/E
Growth & Margin Winner LCTX
Op Margin -280.3% vs -1412.4% ยท YoY -61.0% vs -55.1%
Momentum & Technical Winner ACRS
1Y -54.9% vs +39.8% ยท 52W Pos 0% vs 26%
Options & Structure Winner LCTX
BREAKDOWN (<1st %ile IV) vs BREAKDOWN (<1st %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
1M Return -21.63%
1Y Return -54.86%
Forward P/E 30.7x
Unified AI Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.44
-1.71% 1D
Market Cap $555.1M
1M Return -10.18%
1Y Return +39.84%
Forward P/E N/M
Unified AI Score
45.2 / 100 HOLD
Tech 42.0 Fund 57.0 Flow 64.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -54.86% ACRS +39.84% Spread: +94.7 pp (ACRS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue ACRS Revenue LCTX Op. Margin ACRS Op. Margin Margin Edge
FY2018 $0M $10M -837.9% -1378.3% LCTX
FY2019 $0M $0M -1106.0% -2627.3% LCTX
FY2020 $0M $10M -1448.4% -785.4% ACRS
FY2021 $0M $10M -1133.6% -1327.1% LCTX
FY2022 $10M $30M -153.2% -302.0% LCTX
FY2023 $10M $30M -276.5% -311.6% LCTX
FY2024 $10M $20M -226.1% -758.2% LCTX
FY2025 $10M $10M -251.6% -975.9% LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (6) vs ACRS (4)
Institutional Metric LCTX ACRS Criterion Row Winner
Market Capitalization Scale $207.4M $555.1M Larger Scale ACRS
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% -55.1% Higher Growth ACRS
Operating Margin (TTM) Profitability -280.3% -1412.4% Higher Margin LCTX
Net Profit Margin Profitability 16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -55.5% Higher ROE LCTX
52-Week Range Position Momentum 0% ($1โ€“$2) 26% ($2โ€“$7) Stronger Trend ACRS
Beta / 30D Volatility Risk Regime 1.39ฮฒ ยท 79% Vol 1.42ฮฒ ยท 69% Vol Lower Realized Risk ACRS
Unified Institutional Score Composite Signal 54.9 / 100 (HOLD) 45.2 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs ACRS Buy Guide
LCTX BREAKDOWN
7d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ACRS BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live ACRS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor ACRS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.